OxInfer
Our Team
-
Ed Burn
Senior Researcher in Epidemiology and Health Economics
-
Xintong Li
Postdoctoral Data Scientist
-
Martí Català Sabaté
Medical Statistician/Data Scientist
-
Daniel Prieto-Alhambra
Professor of Pharmaco- and Device Epidemiology
-
Albert Prats-Uribe
Senior Clinical Research Fellow in Public Health
-
Annika Jödicke
Senior Research Associate in Pharmacoepidemiology
-
Kristin Kostka
DPhil student
-
James Weaver
DPhil student
Oxford distributed analytics for network research group (OxInfer)
The Oxford distributed analytics for network research group (OxInfer) is co-leading the development of analytic pipelines for the Data Analysis and Real World Interrogation Network (DARWIN EU) project. Recently established by the European Medicines Agency, DARWIN EU aids regulatory decision-making by generating evidence from routinely collected healthcare data from across Europe.
To support the process of generating reliable evidence from a distributed network of real world data sources, we are developing analytics which span the gamut of the evidence generation process, from developing reliable phenotypes for identifying study populations to creating web applications for disseminating study results. These build on the foundational work done by the European Health Data & Evidence Network (EHDEN) and the Observational Health Data Sciences and Informatics (OHDSI) community.
Collaborating groups
The OxInfer group works in close collaboration with the Pharmaco- and Device epidemiology group.
RECENT PUBLICATIONS
-
Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study.
Prats-Uribe A. et al, (2021), Bmj, 373
-
The natural history of symptomatic COVID-19 in Catalonia, Spain: a multi-state model including 109,367 outpatient diagnoses, 18,019 hospitalisations, and 5,585 COVID-19 deaths among 5,627,520 people
Burn E. et al, (2020)
-
Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study.
Burn E. et al, (2020), Nat commun, 11
-
Characterising the background incidence rates of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study
Li X. et al, (2021), The bmj